NN101 – SMA SMA Biomarkers Study: Spinal Muscular Atrophy (SMA) Biomarkers in the Immediate Postnatal Period of Development
SMA Biomarker Recruitment Video »
Brochure (PDF) » 
IRB Approved Flyer (PDF) »
NN102 – SPRINT-MS NeuroNEXT is pleased to announce funding for SPRINT-MS:
"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis"
IRB Approved Flyer (PDF) »
NN103 – Beat MG Brochure (PDF) »
MG Disease Overview Video »
NN103 MG Study Video »
Email or call 1-844-MGSTUDY (1-844-647-8839).
NeuroNEXT NN103 Rituximab in MG: Patient Information Webinar on April 10, 2015 »
NeuroNEXT NN103 Study Team Releases Clinical Trial and Myasthenia Gravis (MG) Disease Videos »
NN104 – RHAPSODY NeuroNEXT is pleased to announce funding for our fourth approved trial: "Safety evaluation of 3K3A-APC in ischemic stroke"
NN105 – STAIR NeuroNEXT is pleased to announce funding for the fifth approved trial "An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects with Huntington's Disease (HD)"
IRB Approved Flyer (PDF) »
NN106 – Cyto-C NeuroNEXT is pleased to announce funding for NN106 "Phase II Study of Cytochrome C Oxidase Activity as a Novel Biomarker In Subjects with Newly Diagnosed Primary Glioblastoma Multiforme"
NN107 – Fragile X NeuroNEXT is pleased to announce the funding of NN107 "Phase II Randomized double blind study will examine if the drug AFQ056 can enhance neural plasticity in the form of language learning in young children with fragile X syndrome"